Sep 012020
 

By Talent4Boards Team

Talent4Boards - Great Talent builds Great Boards

– SWITZERLAND, Basel –  BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focuses on developing small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation, today announced the successful completion of a CHF 19 million Series B financing round to advance its two ...

BioVersys adds Dr Ed Holdener to its Board and announces CHF19m Series B financing to advance its clinical trials

BioVersys adds Dr Ed Holdener to its Board and announces CHF19m Series B financing to advance its clinical trials

From:: BioVersys adds Dr Ed Holdener to its Board and announces CHF19m Series B financing to advance its clinical trials

Sorry, the comment form is closed at this time.